期刊文献+

IL-6/STAT3信号通路与肝癌研究进展 被引量:14

Progress in research on IL-6/STAT3 signaling pathway and liver cancer
下载PDF
导出
摘要 IL-6是一种多效细胞因子,主要通过IL-6/STAT3信号通路发挥生物学效应。IL-6在肿瘤微环境中含量丰富,异常激活的IL-6/STAT3信号通路可通过影响肿瘤细胞增殖、迁移、侵袭、血管生成和凋亡等过程参与肝细胞癌(HCC)发生发展。靶向药物可通过阻断该信号通路显著抑制肝癌细胞恶性生物学行为,miRNAs可多靶点作用于IL-6/STAT3信号通路,抑制肝癌发生发展。深入了解IL-6/STAT3信号通路与HCC的关系有助于阐明其发病机制,并为HCC治疗提供新方向。 IL-6 is a pleiotropic cytokine that exerts its biological effects mainly through IL-6/STAT3 signaling pathway.IL-6 is abundant in tumor microenvironment,and abnormally activated IL-6/STAT3 signaling pathway can participate in occurrence and development of hepatocellular carcinoma(HCC)via multiple processes affecting tumor cell proliferation,migration,invasion,angiogenesis and apoptosis.Targeting drugs can significantly inhibit malignant biological behavior of liver cancer cells by blocking this signal pathway.miRNAs can act on IL-6/STAT3 signaling pathway with multiple targets to inhibit occurrence and development of liver cancer.Understanding relationship between IL-6/STAT3 signaling pathway and HCC can help elucidate its pathogenesis and provide new directions for treatment.
作者 柳辉 郭乐 丁淑琴 李元 姜中佳 LIU Hui;GUO Le;DING Shu-Qin;LI Yuan;JIANG Zhong-Jia(School of Clinical Medicine,Ningxia Medical University,Yinchuan 750004,China)
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2021年第13期1656-1662,共7页 Chinese Journal of Immunology
基金 宁夏自然科学基金资助项目(2018AAC03074) 宁夏回族自治区级大学生创新创业训练计划项目(S201910752035) 宁夏医科大学校级项目(XT2017033) 宁夏医科大学临床医学院一流学科开放课题项目(NXYLXK2017A05) 宁夏青年科技人才托举工程项目(TJGC2018079) 宁夏高等学校科学技术研究项目(NGY2018-75)。
关键词 IL-6 STAT3 IL-6/STAT3信号通路 肝细胞肝癌 IL-6 STAT3 IL-6/STAT3 signaling pathway Hepatocellular carcinoma
  • 相关文献

参考文献7

二级参考文献50

  • 1MENG SEN LI, PING FENG LI, FBI YI YANG, SHI PENG HE, Guo GUANG DU, GANG LI1 Department of Biochemistry and Molecular Biology, 2 Department of Biophysics, Health Science Center, Peking University, Beijing 100083, China.The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells[J].Cell Research,2002,12(2):151-156. 被引量:27
  • 2Wang J,Sharma A,Ghamande SA,et al. Serum protein profile atremission can accurately assess therapeutic outcomes and surviv-al for serous ovarian cancer[J/CD]. PLoS One, 2013,8 ( 11 ):e78393.
  • 3Garbers C,Thaiss W,Jones GW,et al. Inhibition of classic sig-naling is a novel function of soluble glycoprotein 130 (sgpl30),which is controlled by the ratio of interleukin 6 and soluble inter-leukin 6 receptor[J]. J Biol Chem,2011,286(50) :42959-42970.
  • 4Rose-John S. IL-6 trans-signaling via the soluble il-6 receptor:Importance for the pro-inflammatory activities of iL-6[J]. Int JBiol Sci,2012,8(9) :1237-1247.
  • 5Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, et al.Serum levels of IL-6 . IL-8 and crp as prognostic factors in epithe-lial ovarian cancer [ J]. Am J Obstet Gynecol,2013,24 ( 3 ):106-113.
  • 6Rath KS, Funk HM,Bowling MC,et al. Expression of solubleinterleukin-6 receptor in malignant ovarian tissue[J/CD]. EurCytokine Netw,2010,203(3) :230 e231-238.
  • 7Yigit R,Figdor CG,Zusterzeel PL,et al. Cytokine analysis as atool to understand tumour-host interaction in ovarian cancer[J].Eur J Cancer,2011,47(12) : 1883-1889.
  • 8Lo CW,Chen MW,Hsiao M,et al. IL-6 trans-signaling in forma-tion and progression of malignant ascites in ovarian cancer [J].Cancer Res,2011,71(2) :424-434.
  • 9Guo Y.Nemeth J,O,Brien C,et al. Effects of siltuximab on theiL-6-induced signaling pathway in ovarian cancer[J]. Clin CancerRes,2010,16(23):5759-5769.
  • 10Alberti C,Pinciroli P. Valeri B,et al. Ligand-dependent egfr acti-vation induces the co-expression of IL-6 and pai-1 via the nfkbpathway in advanced-stage epithelial ovarian cancer [J]. Onco-gene, 2012 ,31(37) : 4139-4149.

共引文献52

同被引文献261

引证文献14

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部